An Intervention Study of Compound Silymarin in Patients With Non-alcoholic Fatty Liver Disease

Inclusion Criteria: * Subject's BMI is ≥ 22.0 kg/m2 and \< 33.0 kg/m2; * Subject is diagnosed with NAFLD according to the Chinese Non-alcoholic fatty liver disease prevention guide 2018; * A mildly elevated of ALT level (≥ 30 U/L for male, ≥ 19 U/L for female) or an AST/ALT ratio \< 1.0; * Must be able to swallow tablets. Exclusion Criteria: * ≥ 30 grams of alcohol/day for male and ≥ 20 grams of alcohol/day for female; * Patients with certain hepatic diseases such as gallstones, hepatitis C, autoimmune hepatitis, and hepatolenticular degeneration which can lead to fatty liver disease; * Be taking medicines or supplements that would influence the liver function, lipid metabolism; * Patients with total parenteral nutrition, inflammatory bowel disease, celiac disease, hypothyroidism, Cushing syndrome, Mauriac syndrome, etc; * Patients with hereditary diseases, coronary heart disease, mental disorder, cancer, cirrhosis and renal disease; * Body weight change are more than 10% in previous 3 months; * Patients who have participated in or are participating in other clinical trials within 3 months of their first administration of the study product; * Subjects are allergic to the ingredients in the test or control samples; * Woman who is pregnant or breastfeeding; * Subjects cannot meet the requirements of compliance in the pre-experiment period; * Subjects who fail to sign the informed consent forms.